SCHEDULE: 3D Investment Partners Adjusts MediciNova Stake

3D Investment Partners and 3D Opportunity Master Fund have amended their Schedule 13D filing concerning MediciNova Inc., reporting a reduction in beneficial ownership and the lapse of an observer appointment right.

Summary

• 3D Investment Partners Pte. Ltd. and 3D Opportunity Master Fund (collectively, the 'Reporting Persons') have filed an amendment to their Schedule 13D regarding their holdings in MediciNova Inc.
• As of September 25, 2026, the Reporting Persons may be deemed to beneficially own approximately 9.9% of MediciNova's outstanding common stock, totaling 4,862,047 shares.
• This represents a decrease from previous filings, with 640,000 shares sold in a private sale on September 25, 2026, for JPY 425 (approximately US$ 2.7) per share.
• The Reporting Persons have also entered into cash-settled total return swap agreements (Cash-Settled TRS) providing economic exposure to an additional 456,637 notional shares (approximately 0.9% of outstanding shares), but these do not confer voting or dispositive power.
• The Reporting Persons' Observer Appointment Right under the Shareholder Rights Agreement lapsed as of 2024, meaning they no longer have an observer on MediciNova's board.
• The Reporting Persons intend to review their investment and reserve the right to change their intentions regarding their holdings, considering various factors including the Issuer's financial position, strategic direction, and market conditions.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing, primarily due to a reduction in beneficial ownership and the lapse of an observer appointment right, with no significant positive developments or strategic shifts indicated.

Positives

• The Reporting Persons maintain a significant beneficial ownership stake of 9.9% in MediciNova Inc., indicating continued interest in the company.
• The company's outstanding shares are reported as 49,221,246 as of August 11, 2026, providing a clear basis for ownership percentage calculations.

Negatives

• The Reporting Persons sold 640,000 shares of MediciNova Inc. on September 25, 2026, reducing their direct beneficial ownership.
• The Reporting Persons' Observer Appointment Right under the Shareholder Rights Agreement lapsed in 2024, removing their ability to have a representative attend board meetings.
• The Cash-Settled TRS agreements provide economic exposure but do not grant voting or dispositive power over the underlying shares, limiting direct influence.

Risks

• The Reporting Persons' intention to review their investment means their future actions, including further sales or acquisitions, are uncertain.
• The lapse of the Observer Appointment Right could reduce the Reporting Persons' direct insight into board-level decisions and strategic direction.

Future Outlook

The Reporting Persons intend to review their investment in MediciNova Inc. and reserve the right to change their intentions regarding any or all matters related to their investment. Their future actions will consider various factors including the Issuer's financial position, strategic direction, board actions, business prospects, and general market conditions.

Management Comments

• "As part of its periodic evaluation of their investment in the Issuer, the Reporting Persons intend to review their investment in the Issuer."
• "The Reporting Persons specifically reserve the right to change their intention with respect to any or all of such matters."
• "In reaching any decision as to their course of action (as well as to the specific elements thereof), the Reporting Persons currently expect that they would take into consideration a variety of factors, including, but not limited to, the following: the Issuer's financial position and strategic direction; actions taken by the Issuer's Board of Directors; the Issuer's business and prospects; other developments concerning the Issuer and its businesses generally; other business opportunities available to the Reporting Persons; changes in law and government regulations; general economic and industry conditions; tax considerations; and money and stock market conditions, including the market price of the securities of the Issuer."

Industry Context

StockSavvy.ai notes that Schedule 13D filings are common for significant institutional investors and activist funds. The reduction in direct ownership while maintaining economic exposure through derivatives is a strategy sometimes employed to manage capital or hedge positions. The lapse of an observer right suggests a potential shift in the investor's engagement level or strategy.

Corporate Governance

Stakeholder Impact

• Shareholders: The sale of shares by a significant holder could be perceived negatively, potentially impacting share price. However, the continued 9.9% ownership and economic exposure through TRS may indicate ongoing strategic interest.
• Management/Board of Directors: The lapse of the observer right reduces direct input from these Reporting Persons into board proceedings, potentially altering dynamics.
• Creditors/Suppliers: No direct impact indicated in this filing.

Next Steps

• The Reporting Persons will continue to review their investment in MediciNova Inc.
• The Reporting Persons may adjust their holdings or strategy based on their review and market conditions.

Key Dates

Recommendation

The filing indicates a reduction in direct shareholding and the lapse of an observer right, which are not strong positive signals. However, the Reporting Persons retain a significant stake (9.9%) and economic exposure via derivatives, suggesting continued interest. Without clear positive or negative catalysts for MediciNova itself, a 'hold' recommendation is appropriate, reflecting the neutral to slightly negative sentiment of the filing and the uncertainty of future investor actions.

Keywords

MediciNova Inc., Schedule 13D, Beneficial Ownership, Investment Review, Shareholder Rights Agreement, Total Return Swap, Securities Exchange Act